Sarepta FDA Request - Search News

Order byBest matchMost fresh

News

FDA Shuts Down Sarepta Gene Therapy Trials

Sarepta under pressure: FDA requests halt of Elevidys shipments

Sarepta Therapeutics (SRPT) stock is in focus after the US Food and Drug Administration (FDA) asked the company to halt shipments of Elevidys, a treatment that has been linked to multiple patient deaths.

Continue reading

BioPharma Dive · 8h

FDA asks Sarepta to stop shipping Duchenne gene therapy

· 3d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

MedPage Today10h

Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths

The agency also revoked Sarepta's platform technology designation for AAVrh74 Friday and issued a safety communication saying ...

1don MSN

Sarepta’s Risky Gamble: Gene Therapy Stays on Market Despite FDA Request

When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

BioPharma Dive11h

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results